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ABSTRACT
The absence of specific guidance on how to use
ultrasound (US) to diagnose and manage patients with
inflammatory arthritis, especially with rheumatoid
arthritis (RA) has hindered the optimal utilisation of US
in clinical practice, potentially limiting its benefits for
patient outcomes. In view of this, a group of
musculoskeletal US experts formed a working group to
consider how this unmet need could be satisfied and to
produce guidance (additional to European League
against Rheumatism (EULAR) imaging recommendations)
to support clinicians in their daily clinical work. This
paper describes this process and its outcome, namely
five novel algorithms, which identify when US could be
used. They are designed to aid diagnosis, to inform
assessment of treatment response/disease monitoring
and to evaluate stable disease state or remission in
patients with suspected or established RA, by providing
a pragmatic template for using US at certain time points
of the RA management. A research agenda has also
been defined for answering unmet clinical needs.
Recently, the European League against Rheumatism
(EULAR) has produced recommendations for using
imaging in rheumatoid arthritis (RA) management
to aid diagnosis, assessment of prognosis, assess-
ment of treatment response/disease activity and to
support remission surveillance.1 How these recom-
mendations should be applied, however, is open to
interpretation.
Among the different imaging techniques, ultra-
sound (US) has shown to be of particular help in
the diagnostic workup of RA, in guiding treatment
decisions and in monitoring disease activity and
remission. Despite the difference in the quality of
the US machines2–4 and the possible different level
of experience of the operators, published data
support the value of using US in the management
of patients with inflammatory arthritis.1 5 This evi-
dence has encouraged many rheumatologists to
embrace US in their clinical practice.6 The expan-
sion of US in rheumatology has occurred alongside,
and is complementary to, the acceptance of the
treat-to-target model, in which disease activity and
response to treatment must be closely monitored.7
The prompt diagnosis of RA and early initiation
of disease-modifying antirheumatic drugs
(DMARDs) reduce inflammation, limit disease pro-
gression, control symptoms and minimise func-
tional loss.8–10 According to the American College
of Rheumatology (ACR)/EULAR classification cri-
teria,11 a patient with synovitis can be classified as
having RA if a certain number of joints with syno-
vitis are detected or if bone erosions are present.
However, clinical examination and conventional
radiography (CR) are neither sensitive nor accurate
enough to detect disease activity and structural
damage in early disease.12–15
In contrast, US is able to detect synovitis at pres-
entation and differentiate between intra-joint syn-
ovial inflammation and other causes of symptoms/
swelling, such as tenosynovitis, bursitis and other
soft tissue lesions.16–20 This is also reflected in the
ACR/EULAR classification criteria, in which
US-detected synovitis in clinically unaffected joints
may be used to increase the number of involved
joints to satisfy the fulfilment of the classification
criteria.21 Moreover, the earlier the patients are
diagnosed and treated, the more likely they are to
achieve remission and subsequently not flare if
treatment is reduced.22
Once the presence of RA is confirmed, the
optimal management requires tight therapeutic
control for setting remission as primary treatment
goal as stated by the EULAR recommendations for
the management of RA.23 These recommendations
underline that even patients with long-standing
disease should be able to achieve stability with low
disease activity (LDA). Therefore, an early, accurate
assessment of treatment response/level of inflamma-
tion is essential. US offers objective information on
how synovitis is responding to treatment which can
be either the first DMARD in early RA or a change
of therapy in more established disease.24 25 It can
confirm a good response, identify a poor response
and detect a loss of response.
The use of US to monitor patients considered to
be in remission can help predict those likely to
suffer subsequent joint damage and flare-up of
disease.26 It has been shown that between 15% and
62% of patients considered to be in remission
based on clinical examination have synovial hyper-
trophy on US.27–29
Between 19% and 30% of patients also have
radiographic progression on further evaluation.30 It
has also been suggested that remission should only
be defined in the absence of synovitis as shown by
US.31
Although EULAR recommendations and pub-
lished data support the use of US in several areas of
RA management, they do not provide specific
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guidance on how to use US, which may result in an inconsistent
or suboptimal utilisation of US and potentially the suboptimal
treatment of patients. Therefore, there is a clear need for prag-
matic, expert guidance for clinicians wishing to use US in their
daily practice.
To address this need, a group of musculoskeletal US experts
reviewed the available literature and discussed the best approach
for developing pragmatic suggestions for the use of US in the
daily management of patients with suspected or established RA.
The authors also reflected on the areas for which there is a
paucity of evidence, by producing a research agenda for optimis-
ing the application of US in clinical practice.
METHODS
A two-step procedure was followed. The expert group, com-
posed of 10 rheumatologists experienced in musculoskeletal US
representing seven European countries (Denmark, England,
France, Germany, Hungary, Italy and Spain), met twice in
September 2014 and January 2015. The objectives of these
meetings were: (1) to formulate key clinical questions related to
the use of US in RA, (2) to identify and critically appraise the
available evidence and (3) to generate pragmatic algorithms on
the application of US in suspected or established RA based on
both evidence and expert opinion. To meet the first and second
objectives, the group was divided into three task forces: (1)
diagnosis, (2) assessment of treatment response and (3) assess-
ment of disease state. Each task force used the search terms of
the systematic literature review (SLR) used for producing the
EULAR imaging recommendations,1 which was proposed as
online supplementary material for the published article. They,
therefore, updated the literature search to January 2015 using
the same MeSH (Medical Subject Headings) terms. Any paper
published after this date was incorporated if relevant for the
purpose of the project (narrative literature search). The articles
were analysed from the perspective of three key questions: (1) the
role of US for improving the diagnosis of RA, (2) the role of US
for monitoring response to treatment and (3) the role of US in
evaluating subclinical disease activity in stable disease. It was
decided not to create a separate research question for addressing
the specific role of US as a predictive tool for diagnosis, severity
or response to treatment, as few data are available for supporting
a separate question. However, prediction aspects have been inves-
tigated in each of the three above-mentioned research questions.
The results of the literature review were detailed and consid-
ered by the group to establish what is known (evidence) and
what is unknown or uncertain (more evidence needed). In cases
of uncertainty or lack of evidence, it was agreed that consensus
expert opinion should guide the best use of US in these particu-
lar circumstances and future research questions should be devel-
oped to reduce uncertainty. A 100% agreement (ie, unanimous)
was required in case of lack of literature evidence. Five algo-
rithms were finalised according to this process (figures 1–5).
RESULTS AND DISCUSSION
Using US to establish or confirm a diagnosis of RA
Since 2010, new classification criteria, the ACR/EULAR 2010
criteria, has been proposed for helping to classify patients suf-
fering from RA at an earlier stage of disease than by using the
modified ACR 1987 criteria.11 This means that patients can
benefit from an appropriate treatment before the structural
damage lesions detected by CR appear.
However, some studies have supported the fact that even
these new criteria can lack both sensitivity (ie, delaying diagnosis)
and specificity (ie, overestimating the presence of true RA).32–37
There is substantial evidence to show that US supports a more
accurate and sensitive diagnosis of RA than both clinical assess-
ment and CR.12–14 According to EULAR imaging recommenda-
tions, the detection rate of synovitis at the hand and wrist using
US was double than that obtained with clinical examination.1
Patients assessed by US are likely to fulfil the ACR/EULAR cri-
teria for RA at an earlier stage of their disease than those
assessed using conventional assessment.7 32 38 39
Figure 2 Flow chart showing the ultrasound (US) evaluation in
patients who fulfil American College of Rheumatology (ACR)/European
League against Rheumatism (EULAR) criteria. Purple rectangle denotes
population of interest (or starting point); blue-green rectangles denote
possible paths of the algorithm and red rectangle denotes final
diagnosis.
Figure 1 Flow chart showing the ultrasound (US) evaluation in
patients at risk of rheumatoid arthritis (RA) or suspected RA. Purple
rectangle denotes population of interest (or starting point); blue-green
rectangles denote possible paths of the algorithm and red rectangle
denotes final diagnosis. ACPA, anti-citrullinated peptide antibody; ACR,
American College of Rheumatology; EULAR, European League against
Rheumatism; RF, rheumatoid factor.
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In addition, US may be particularly useful for the differential
diagnosis of RA, as it can differentiate between joint inflamma-
tion and tenosynovitis, bursitis and other soft tissue lesions that
can mimic clinical synovitis.19 20
Recent data suggest that Doppler US can detect subclinical
RA in at-risk patients who are seropositive (for rheumatoid
factor or anti-citrullinated peptide antibodies (ACPAs)) but who
have not yet developed clinical signs of inflammation.40 41 Both
the qualitative and quantitative features of this subclinical
inflammation have been shown, in seronegative patients, to
predict future clinical progression to RA.42 The value of adding
US to routine assessment seems to be greatest in ACPA-negative
patients.42
The experts, therefore, proposed three potential uses of US
during the diagnostic workup, and in the absence of definite
erosions at CR: (1) to determine whether subclinical synovitis is
present in at-risk patients with no sign of inflammation on clin-
ical examination; (2) to reassess patients whose clinical synovitis
does not fulfil ACR/EULAR criteria and (3) to confirm the diag-
nosis in patients who fulfil the ACR/EULAR criteria on clinical
examination, but for whom there is a doubt to be considered as
‘false-positive’ or where synovitis is the outcome (eg, on entry
to a study).
Figures 1 and 2 summarise these proposals. In figure 1, it is
suggested that patients considered at risk of RA due to symp-
toms and/or seropositivity or with clinically suspected RA
should undergo an US evaluation along with a full clinical
examination, including CR. This additional evaluation could
improve patient outcome by facilitating the application of ACR/
EULAR criteria, either by increasing the number of inflamed
joints or, in absence of clinically detected inflammation, by con-
firming the presence of subclinical synovitis, allowing, therefore,
Figure 3 Flow chart showing the
ultrasound (US) evaluation of
therapeutic response in patients with
rheumatoid arthritis (RA) starting
csDMARDs or bDMARDs. Purple
rectangle denotes population of
interest (or starting point); red text
denotes csDMARDs; blue text denotes
bDMARDs; blue-green rectangles
denote possible paths of the
algorithm; red rectangle denotes
proposed path for csDMARDs
population and blue rectangle denotes
proposed path for bDMARDs.
bDMARDs, biological
disease-modifying antirheumatic drugs;
csDMARDs, conventional synthetic
disease-modifying antirheumatic drugs;
TNFi, tumour necrosis factor inhibitor.
Figure 4 Flow chart showing the ultrasound evaluation in patients
with rheumatoid arthritis with loss of treatment response (both
conventional synthetic or biological disease-modifying anti-rheumatic
drugs). Purple rectangle denotes population of interest (or starting
point) and blue-green rectangles denote possible paths of the
algorithm.
Figure 5 Flow chart showing the ultrasound evaluation in assessing
remission or low disease activity in patients with rheumatoid arthritis.
Purple rectangle denotes population of interest (or starting point) and
blue-green rectangles denote possible paths of the algorithm.
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a diagnosis at an earlier stage. US may also be helpful in exclud-
ing the presence of RA in case of normality of the US evalu-
ation. In the latter cases, therapeutic management will be
adapted according to the presence of concomitant prognostic
factors.
Additionally, an US examination even in patients fulfilling
ACR/EULAR criteria (figure 2) at baseline evaluation has been
proposed. The use of US in those patients may help to detect
false-positive patients by excluding other causes of joint path-
ology such as inflammatory flare of osteoarthritis or crystal-
related diseases, based on the US appearance of typical findings
(ie, osteophytes, crystals, presence of double contour, etc). It is
still a matter of debate as to how to determine the true ability of
US to exclude diseases other than RA. There is some evidence
to recommend specific cut-off values for greyscale (GS) and
Doppler US to confirm the presence of inflammation at joint
level for the diagnosis of RA.38 43 Increasing cut-off thresholds
has been shown to increase the specificity for RA but at the
expense of decreased sensitivity.32
Research agenda
▸ Threshold of normality of US findings
▸ Minimal number of joints to scan for diagnostic purposes
▸ Predictive validity of subclinical, US-detected synovitis in
terms of ‘window of opportunity’
Using US in assessing response to treatment
Published data have consistently shown that US can detect a
response in US-detected joint inflammation after treatment (for
between 1 week and 1 year) in patients treated with either con-
ventional synthetic DMARDs (csDMARDs) or biological
DMARDs (bDMARDs).15 44–60 Both GS and Doppler are at
least as sensitive as clinical examination and laboratory markers
in detecting changes in patients with RA who have initiated
effective therapy.60 The more comprehensive the US examin-
ation, the more sensitive it is in detecting change.51 However,
reduced-joint US assessments have also shown a good sensitiv-
ity,47 48 55 60 61 focusing either on a few target joints such as the
wrist, metacarpophalangeal and metatarsophalangeal joints or
on a few small joints plus one or two large joints.47 48 55 60 62
Based on the literature review and experts’ opinion, it is pro-
posed that patients with RA on either csDMARDs or
bDMARDs should undergo assessment with US at baseline treat-
ment and after 3–6 months of treatment to assess initial
response, in order to help clinicians tailor therapy (maintaining,
changing or tapering). Figures 3 and 4 summarise the pragmatic
algorithms for using US in assessing treatment response either
under csDMARDs or bDMARDs.
Figure 3 shows the proposed use of US in patients with RA
on csDMARDs or bDMARDs to (1) re-evaluate non-
inflammatory causes of poor clinical response in patients
without US synovitis (A) (2) support change of treatment (ie,
escalation) in patients with poor clinical response and confirmed
US synovitis (B), (3) maintain or taper the dosage in patients
with good clinical response and absence of US synovitis (C) and,
finally, (4) assess change of therapy (ie, escalation) in patients on
csDMARDs with good clinical response but significant US syno-
vitis (D) or in case of patients on bDMARDs to possibly main-
tain the therapy, as the importance of synovitis in patients on a
bDMARD is less certain.
Finally, figure 4 shows the suggested use of US to support
change of treatment versus investigation of non-inflammatory
causes in patients with loss of clinical response with US synovitis
or without US synovitis, respectively, independently of the
treatment (csDMARDs and/or bDMARDs). In particular, in
such patients with a good clinical response, the presence of US
synovitis would make tapering of treatment inadvisable.63
Detection of synovitis is important since Doppler, as well as
GS, US-detected synovitis is able to predict structural damage in
both early RA31 41 64–68 and in established disease.69 70 The
importance of synovitis in patients on a bDMARD needs
further investigation.
Some data suggest that US-detected bone erosions may also
be sensitive to change.59 71
By evaluating the real presence of inflammation and by
excluding other causes of joint pain (such as joint deformity or
periarticular lesions) the use of US in assessing response to
therapy can be of a great help in clinical practice. The same con-
sideration expressed in the previous section on diagnosis and
the capability of US to discriminate different diseases is also of
debate in this context. In addition, recent studies question the
benefit of US for managing patients with early RA for reaching
a therapeutic target (such as LDA) according to disease activity
score (DAS) values.24 25 33 In fact, in these two randomised,
controlled studies, the ‘target control’, based on US data, did
not do better than the target control based on DAS 28, either
for DAS response over time or for radiographic progression.
However, it is worth noting that in both studies the achieve-
ment of a DAS remission was higher in the US group. Further
studies, with a higher number of patients, in an international
multicentre setting, on patients with RA having different
disease duration and different disease activity (and with differ-
ent endpoints/outcomes) are needed for confirming or refuting
these results.
Research agenda
▸ Is Doppler alone sufficient to monitor response to therapy?
▸ Should the same US mode (GS versus Doppler, or both com-
bined) be applied in early and established disease?
▸ Which reduced joint assessments are most sensitive to change
in early and established RA?
▸ Should tenosynovitis be included in the US evaluation of
RA?
▸ How often should US be used to monitor therapeutic
response?
▸ What is the long-term impact on RA outcomes of US
evaluation?
▸ Should a strategy trial be performed only in international
multicentre settings?
US in assessing remission/LDA state
Sustained remission is important as flares predict erosive pro-
gression over time and functional disability.72–74 Studies have
shown that in patients in remission determined either by phys-
ician or by use of various remission criteria, subclinical synovitis
is present in both GS and Doppler27–29 and that the amount of
synovitis detected by US is independent of whether the patient
is receiving csDMARDs or bDMARDs.75 Studies of patients on
csDMARD therapy have shown that a Doppler signal of >1 is
associated with erosive progression on X-ray over time76 and
synovitis shown by GS US indicate the occurrence or worsening
of bone erosions.30
The presence of subclinical synovitis with a Doppler signal of
>1 increases the risk of disease flare up in patients with RA in
remission26 31 77 whereas having Doppler-negative joints is the
best predictor for not experiencing a flare.31 The need to taper
or stop bDMARD treatment should also be carried out so flares
are avoided. Patients with a high US score on GS and Doppler
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are more likely to relapse when stopping or tapering biological
therapy than patients with a low score.63 78
Based on the literature review and experts’ opinion, patients
with RA on both csDMARDs and bDMARDs should undergo
assessment with US. The best time decided by the expert is at
least after 6 months of clinical stable disease state to determine
possible need for treatment alterations (increased or tapered).
Figure 5 shows the proposed algorithm for using US in
patients on both csDMARDs and bDMARDs who are in stable
clinical state. If the US examination does not reveal signs of
synovitis, then either the current treatment must be continued
or the tapering of the treatment must be considered. If the US
examination reveals synovitis, change or optimisation of the
current treatment must be considered.
Research agenda
▸ Define the threshold of US remission according to the dur-
ation of the disease
▸ Explore if all treated patients with RA achieve US-defined
remission
▸ Does achieving US-defined remission improve patient
outcomes?
▸ How frequently should US be used to confirm absence of
disease activity in patients in US-defined remission?
CONCLUSION
Developments in the management of RA in recent years have
produced remarkable improvements in patient outcomes to the
point where almost every patient now has a realistic chance of
achieving either remission or LDA. It is important that imaging
techniques keep pace with these advancements. While clinical
assessment and CR have shown considerable value in the diag-
nosis and monitoring of RA, used alone they do not have suffi-
cient sensitivity to support the current treat-to-target approach.
The addition of targeted US assessment will help improve diag-
nosis and treatment of patients with RA in daily clinical practice
and the algorithmic approach presented in this paper might
help to achieve this goal. In this context, the availability of high-
quality machines with a Doppler setting adapted to the study of
slow flow as observed in inflammatory tissues will permit
greater homogeneity of US reports and an easier and wider util-
isation of US in clinical daily management. In this context, edu-
cational and training tools play a key role in improving the skills
of rheumatologists in US as well as in teaching its pragmatic use
in clinical practice.79
The optimal dissemination and application of the proposed
algorithmic approaches for using US in the management of
patients with new and established RA will require the support of
educational initiatives and training activities. Further multicentre
studies are needed for evaluating the implementation of these
pragmatic approaches on patient outcomes, for evaluating the
feasibility of an US approach and for evaluating the cost-
effectiveness, as compared with standard of care.
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